Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?

Alzheimers Dement (N Y) · 2017 · PMC5651424 · PMID 29067346

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The largest observed (and nominally significant, but exploratory) effect on the ADAS-Cog was seen at the 0.15 mg/kg dose, but not corroborated by data from the DAD at that dose.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.